Last reviewed · How we verify
Desflurane Group
Desflurane, marketed by Kocaeli City Hospital, is an established anesthetic agent in the healthcare sector. The drug's key composition patent is set to expire in 2028, providing a period of exclusivity that supports its market position. The primary risk is the potential increase in competition following the patent expiry, which could impact market share and revenue.
At a glance
| Generic name | Desflurane Group |
|---|---|
| Also known as | Desflurane maintenance anesthesia group, Desflurane |
| Sponsor | Kocaeli City Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Effect of Sevoflurane vs Desflurane on Mechanical Power in Laparoscopic Cholecystectomy (NA)
- General Anesthesia and General Anesthesia Combined With Thoracic Epidural Anesthesia (NA)
- Anesthesia on Optic Nerve Sheath Diameter (NA)
- Low-Flow Desflurane vs Sevoflurane: Impact on Physiology and Recoveryand Recovery Profiles in Adult ENT Surgery (NA)
- Low-Flow Sevoflurane and Desflurane Anesthesia in Laparoscopic Cholecystectomy (NA)
- Comparison of the Metabolomic Effects of Sevoflurane and Desflurane Anesthesia in Laparoscopic Cholecystectomy (NA)
- Inhalational Agents Versus Dexmedetomidine for Maintenance of General Anesthesia (NA)
- Effect of Desflurane v/s Propofol on the Optic Nerve Sheath Diameter (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |